disorders, [5] [6] [7] [8] indicating a need for alternative CV biomarkers in these at-risk populations.
GlycA, a complex heterogeneous nuclear magnetic resonance signal originating from mobile glycan residues on plasma glycoproteins, is a novel composite biomarker of systemic inflammation. 9, 10 Recent studies have demonstrated GlycA to be a strong predictor of future CV events, 11, 12 incident type 2 diabetes mellitus, 13, 14 long-term risk of severe infection, 4 and overall mortality. 12 Moreover, GlycA showed promise in the assessment of disease activity, treatment response, and CAD in patients with inflammatory disorders, such as systemic lupus erythematosus and rheumatoid arthritis. [15] [16] [17] [18] Psoriasis, a chronic inflammatory skin disease affecting 2% to 3% of US adults, 19 is associated with chronic systemic inflammation, increased vascular inflammation (VI) by 18-F Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (18-FDG PET/CT), 20, 21 and a greater risk of incident CV events [22] [23] [24] and CV mortality. 25 Traditional risk assessment does not accurately capture the increased CV risk among patients with psoriasis, 26 and many patients with CVD and related events in psoriasis are young 23, 25 with low Framingham Risk Scores (FRSs). 26 As such, psoriasis provides a reliable human model to study the use of novel inflammatory biomarkers for predicting subclinical CVD in chronic inflammatory states.
To understand how GlycA may potentially associate with subclinical CVD and to compare the association between GlycA and subclinical CVD with association between hsCRP and subclinical CVD, we used a 2-stage study design. In the first stage (henceforth PENN cohort), we evaluated patients with psoriasis and healthy controls to determine whether GlycA levels were elevated in psoriasis. In the second stage (henceforth NIH [National Institutes of Health] cohort), we wished to confirm the association between GlycA and psoriasis and to characterize potential relationship between GlycA and subclinical CVD by assessing VI by 18-FDG PET/CT and CAD by coronary computed tomographic angiography (CCTA) to estimate coronary plaque burden. We hypothesized that GlycA would be elevated in psoriasis, associate with skin disease severity, and also directly associate with VI by 18-FDG PET/CT and CAD by CCTA beyond traditional risk factors and hsCRP.
Methods
A total of 412 participants were included in a 2-stage, cross-sectional study design: PENN cohort (n=231; 122 patients with psoriasis and 109 controls) and NIH cohort (n=181; 151 patients with psoriasis and 30 controls). A detailed description of methods and materials including inclusion/exclusion criteria, clinical assessment, detailed imaging procedures, and statistical analyses for both the cohorts are available in the online Data Supplement. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were followed for reporting the findings from both the stages. 27 
Results

Characteristics of the Study Groups
The PENN cohort (Table 1) Figure 1A ), which remained significant after adjustment for age, sex, BMI, and traditional CV risk factors.
The NIH cohort ( 
GlycA Provides Value in Assessing VI and CAD Burden Beyond Traditional CV Risk Factors and hsCRP in Psoriasis
The contribution of GlycA in assessing VI and CAD beyond traditional CV risk factors and hsCRP was first determined using likelihood ratio testing in nested models and second by analyzing receiver operating characteristic curves. GlycA provided maximum value in the estimation of VI beyond hsCRP, when added to fully adjusted models, in both psoriasis (χ Figure 3A1 ). Similar results were observed in predicting CAD (AUC: 95% CI, 0.89, 0.88-0.89 versus 0.92, 0.91-0.92; P<0.01; Figure 3A2 ). Furthermore, GlycA also added incremental value in predicting these measures of subclinical CVD in controls ( Figure 3A3 and 3A4). hsCRP did not add value in predicting CAD or VI above the cohort mean in psoriasis ( Figure 3B1 and 3B2) . Finally, in controls, although hsCRP did not add value to predicting VI ( Figure 3B3 ), it provided value in predicting CAD above the cohort mean ( Figure 3B4 ).
Successful Treatment of Psoriasis With Anti-Tumor Necrosis Factor Therapy Decreases GlycA and Aortic VI by FDG PET/CT
Given the association between GlycA and systemic inflammation, we hypothesized that the treatment of psoriasis would 
Discussion
Using a 2-stage study design in psoriasis and healthy controls, we demonstrated the following major findings: (1) GlycA levels were elevated in psoriasis compared with healthy controls with a dose-response relationship between GlycA and psoriasis skin disease severity; (2) GlycA significantly correlated with hsCRP, inflammatory cytokines, and markers of cardiometabolic disease; (3) GlycA associated with VI by 18-FDG PET/CT and CAD by CCTA beyond traditional CV risk factors in psoriasis; (4) GlycA provided maximum value in the assessment of VI and CAD beyond hsCRP in models adjusted for traditional CV risk in psoriasis; and (5) successful treatment of psoriatic skin inflammation with anti-TNF therapy decreased GlycA levels and VI with the persistence of the association between VI and GlycA post-treatment. Collectively, these findings support the value of GlycA as a promising biomarker of inflammation and subclinical CVD risk in psoriasis.
In recent years, the inflammatory hypothesis of atherosclerosis has generated interest in several potential inflammatory biomarkers for CV disease. These include cytokines, such as IL-6, TNF-α, interferon-γ, and monocyte chemoattractant protein-1); mediators of endothelial activation, such as VCAM-1 (vascular cell adhesion molecule-1), ICAM-1 (intercellular adhesion molecule-1), and E-selectin; and acute phase reactants, such as serum amyloid A and hsCRP. hsCRP, a marker of systemic inflammation, has become a promising candidate because it is a validated prognostic biomarker of CV disease. However, recent evidence demonstrates that hsCRP may not accurately predict CV disease in patients with inflammatory conditions, such as systemic lupus erythematosus, 6 psoriasis, 7 rheumatoid arthritis, 5 and HIV. 8 Furthermore, a large population-based longitudinal study of >10 000 patients showed evidence to suggest that elevated hsCRP may not be a universal feature of chronic inflammation. 4 Collectively, these findings indicate that hsCRP may perform suboptimally in CV risk prediction in patients with chronic inflammatory diseases and suggest a need for alternative CV biomarkers in these vulnerable population.
Contemporary studies to identify new inflammatory biomarkers for CV disease demonstrate the potential for measuring GlycA. GlycA, a nuclear magnetic resonance signal originating from a subset of glycan N-acetylglucosamine residues on enzymatically glycosylated acute-phase proteins, is a biomarker of systemic inflammation. 9, 10 Recent studies involving >25 000 subjects found GlycA to be predictive of 15-year CV events, 11 incident diabetes mellitus, 13 and all-cause mortality. 12, 28 Fischer et al 29 also found a 67% and 55% increase in mortality for every SD increase in GlycA, in 2 independent populations totaling >17 000 healthy adults. Furthermore, these large population studies in subjects without pre-existing inflammatory diseases have revealed that GlycA either conferred additional value beyond traditional biomarkers of inflammation, such as hsCRP, IL-6, ICAM-1, and fibrinogen, or that it was equivalent to these traditional biomarkers in predicting long-term CV and all-cause mortality.
11,12,28 Strikingly, GlycA also showed associations with BMI and fitness among adolescents, 30 suggesting its role even in the early stages of cardiometabolic dysfunction. In addition, in inflammatory states, GlycA associated with disease activity and CHD among rheumatoid arthritis patients, 15, 18 and it was elevated in patients with systemic lupus erythematosus compared with controls. 16 Finally, GlycA also associated with disease activity in systemic lupus erythematosus and revealed improved levels subsequent to treatment. 17 With increased systemic inflammation and VI, 20, 21 higher prevalence of diabetes and other traditional CV risk factors, 31, 32 and a greater risk of CV disease 33 as well as CV 23, 25 and cerebrovascular events 22 psoriasis provides a reliable human model to understand how inflammatory biomarkers perform in CV risk assessment in an inflammatory disease state. In the present study, we demonstrated that GlycA associated with VI and CAD beyond hsCRP and traditional risk in psoriasis, and GlycA provided value in the assessment of subclinical CVD independent of traditional risk factors. Since GlycA provides a composite measurement of human inflammatory glycoproteins, it may capture a broader, summative profile of systemic inflammation. 10 Together, these findings suggest that GlycA may assess both systemic inflammation and CVD risk more accurately when compared to hsCRP in chronic inflammatory conditions.
GlycA levels recently were shown to be stable in healthy individuals for >10 years, barring a clinical change. 4 However, whether GlycA levels respond to anti-inflammatory treatment is unknown. We found that the treatment of skin disease with anti-TNF therapy led to reductions in GlycA and VI, suggesting that GlycA may be a reliable biomarker for disease severity, subclinical CVD risk, and treatment response in psoriasis. Furthermore, the association between VI and GlycA persisted post-treatment suggesting that it may be a robust biomarker of CVD. Given the known relationship between VI by 18-FDG PET/CT and prospective CV events, 34, 35 our results suggest that this achieved reduction in GlycA may correspond with a concomitant reduction in CV risk; however, randomized interventional trials are required to answer this question.
There are limitations to this current study, which warrant mention. First, the sample size of controls in the second stage of the study was limited, as was the sample size of the treatment cohort. Furthermore, given the cross-sectional design, our study cannot assess causality. Finally, we did not examine the association of GlycA with hard CV end points. Despite these limitations, this is the first study, to our knowledge, of GlycA in psoriasis, to show an association between GlycA and subclinical CVD using multimodality imaging in an inflammatory state, and also the first study to perform a systematic comparison between GlycA and hsCRP in subclinical CVD assessment. In addition, both VI by 18-FDG PET/CT 34, 36 and CAD by CCTA 37, 38 are validated surrogates for prospective CV outcomes. Utilizing these markers in deeply phenotyped cohorts, we provide novel insight into the value of GlycA for assessing subclinical CVD, building on the previously demonstrated association of GlycA with prospective CV events. 11, 12 Because GlycA nuclear magnetic resonance signal is composed of several acute phase reactant glycoproteins, deeper physiological studies to enhance our understanding of GlycA pathophysiology are warranted. Furthermore, from the emerging evidence and findings of our study, GlycA may be used as a risk factor in epidemiological studies and a potential surrogate end point in clinical trials of anti-inflammatory treatment. However, larger studies will be needed to confirm these findings before the broad scale use of GlycA in trials. Moreover, GlycA measurement may become more widespread with the In conclusion, our study provides strong evidence for an association between GlycA and psoriasis as well as GlycA and subclinical CVD in psoriasis. Furthermore, GlycA predicted VI and CAD beyond hsCRP. Finally, after anti-TNF treatment, we found a decrease in GlycA levels and VI with the persistence of the relationship between GlycA and VI. Taken together, these findings support a potential role of GlycA in CV risk assessment in an inflammatory state beyond hsCRP. Eventually, GlycA may be considered in patients with psoriasis in addition to hsCRP for CVD assessment; however, larger studies are needed to further confirm these findings. Figure 3 Continued. hsCRP adds value in predicting greater total burden of coronary artery disease (4), but not vascular inflammation (3) in controls; however, it fails to add any value in predicting vascular inflammation and coronary artery disease in psoriasis (1 and 2) . Mean values of vascular inflammation and coronary artery disease burden were used to convert these continuous variables into dichotomous variables, such that values ≥mean were designated as 1 and values <mean were designated as 0.
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What Is Known?
• GlycA is a nuclear magnetic resonance-derived signal, originating from mobile glycan residues on plasma glycoproteins, is an emerging biomarker of systemic inflammation associated with all-cause mortality and future cardiovascular events.
• Psoriasis is a chronic inflammatory skin disease associated with great- What New Information Does This Article Contribute?
• GlycA was associated with the severity of psoriasis skin disease in a dose-dependent fashion measured by body surface area and Psoriasis Area Severity Index (PASI).
• GlycA was associated with both VI by 18-FDG PET/CT and coronary artery disease burden by coronary computed tomographic angiography beyond traditional cardiovascular risk factors and added incremental value beyond high-sensitivity C-reactive protein in psoriasis.
• Treatment of psoriasis with anti-tumor necrosis factor therapy led to a decrease in GlycA levels and VI, and GlycA maintained a strong relationship with VI after treatment.
SUPPLEMENTAL MATERIAL
Methods and Materials
Design
A total of 412 participants were included in a two-stage, cross-sectional study design: PENN cohort (n=231; 122 psoriasis patients and 109 controls) and NIH cohort (n=181; 151 psoriasis patients and 30 controls).
PENN Cohort
In the PENN cohort, psoriasis patients (n=122) with no history of clinical CV disease were consecutively enrolled over a six-month period. Absence of CV disease was defined as no CV symptoms, absent electrocardiographic findings consistent with ischemia or infarction, and no history of positive stress test or revascularization. Control cohort (n=109) without psoriasis was chosen from a study of healthy participants in Philadelphia matched by age and sex to the psoriasis cohort from the SIRCA study 1 (Study of Inherited Risk of Coronary Atherosclerosis) and was purposely larger to understand the association of GlycA with psoriasis. All patients underwent clinical assessment at the University of Pennsylvania Clinical and Translational Research Center and psoriasis severity assessment using body surface area (BSA) measurement by a dermatologist. Plasma Hs-CRP levels were assayed with the use of a high-sensitivity latex turbidimetric immunoassay (Wako Ltd) and GlycA levels were derived from NMR spectroscopy (LabCorp). Study approval was obtained from the University of Pennsylvania Institutional Review Board.
NIH Cohort
The NIH cohort included consecutively enrolled psoriasis patients (n=151) from the Psoriasis, Atherosclerosis and Cardiometabolic Disease Initiative (NCT01778569), from January 2013 until October 2015, as well as 30 healthy controls, who were matched to psoriasis patients by age and sex at an apriori decided ratio of 5:1. Psoriasis patients were required to have a formal diagnosis of psoriasis confirmed by an internist, dermatologist or rheumatologist. Psoriasis patients were excluded from the study if they had any comorbid condition known to promote cardiovascular disease (CVD) or systemic inflammation, such as known CV disease, defined as any major adverse cardiovascular event, including Myocardial Infarction, stroke, unstable angina within 5 years from their enrollment in the study, uncontrolled hypertension, malignancy within 5 years, HIV, active infection within the past 72 hours, and major surgery within 3 months. Healthy controls were excluded by any of the following conditions: pregnancy, breastfeeding, malignancy (excluding non-melanoma skin cancer), active infection within 3 months requiring antibiotics, CV disease, diabetes, liver disease, collagen vascular diseases, body mass index >40kg/m 2 or glomerular filtration rate <60mL/min. A dermatologist assessed psoriasis severity by both the Psoriasis Area Severity Index (PASI) score and BSA affected. Both groups underwent the same clinical assessment and testing. Clinical parameters including blood pressure, height, weight, waist and hip circumferences were measured. Laboratory parameters including fasting blood glucose, fasting lipid panel, white blood count with differential, and systemic inflammatory markers including hsCRP and erythrocyte sedimentation rate were evaluated in an accredited clinical laboratory. Similar criteria for inclusion and exclusion of healthy volunteers are published in our earlier work 2 . GlycA was measured by NMR Spectroscopy (LabCorp).
18-FDG PET/CT scans were analyzed to derive target-to-background ratio values to quantify VI. Furthermore, CAD was assessed using dedicated software to quantify total coronary plaque burden from CCTA scans as previously described 3 . Study approval was obtained from the National Heart, Lung, and Blood Institute Institutional Review Board in accordance with the Declaration of Helsinki. All guidelines for Good Clinical Practice and those set forth by the NIH Radiation Safety Commission and in the Belmont Report (National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research) were followed. All study participants provided written informed consent. Other
